Skip to main content
ARCT logo

ARCT · Arcturus Therapeutics Holdings Inc. · Investor Relations

Track ARCT — free
$7.45 -0.15 (-1.97%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$214.73M
Shares
28.82M
Volume · Nov 20 602K Avg daily vol (3M) 883.08K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-16 Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration

$50 Million Strategic Investment in Arcturus at an 80% Premium Proceeds to accelerate development of ARCT-2601 for OTC Deficiency and clinically validate Arcturus’ LUNAR 2.0™ next-generation mRNA platform SAN DIEGO --(BUSINESS WIRE)--Nov. 16, 2026-- Arcturus Therapeutics Holdings Inc.

2026-11-05 Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress

ARCT-032 (CF) Phase 2 enrollment completion YE 2026; data presentation Q2 2027 ARCT-2601 (OTC Deficiency), the first mRNA therapeutic candidate utilizing LUNAR 2.0™, Phase 2 dosing planned to begin Q1 2027; top-line data H2 2027 Investor conference call at 4:30 p.m.

2026-10-26 Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026

SAN DIEGO --(BUSINESS WIRE)--Oct. 26, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced that it will release its financial results for the quarter

2026-09-23 Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

ARCT-810 generally safe and well tolerated, demonstrating encouraging activity across key urea cycle biomarkers in ongoing Phase 2 study LUNAR 2.0™ produces greater than 30-fold higher protein expression in multiple NHP studies – unlocks new therapeutic opportunities ARCT-2601, an OTC deficiency

2026-09-18 Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

SAN DIEGO --(BUSINESS WIRE)--Sep. 18, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will host a virtual presentation on

2026-08-31 Arcturus Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO --(BUSINESS WIRE)--Aug. 31, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the

2026-08-06 Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026 ARCT-810 (OTC Deficiency) Phase 2 study enrollment and dosing completed; data and regulatory plan to be communicated Q3 2026 Arcturus regains global rights to KOSTAIVE® and infectious

2026-07-28 Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026

SAN DIEGO --(BUSINESS WIRE)--Jul. 28, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for

2026-07-20 Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

SAN DIEGO --(BUSINESS WIRE)--Jul. 20, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following

2026-07-02 Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis

Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights SAN DIEGO --(BUSINESS WIRE)--Jul. 2, 2026-- Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory

2026-05-26 Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

SAN DIEGO --(BUSINESS WIRE)--May 26, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following

2026-05-07 Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Initiated enrollment (Q1 2026) earlier than expected for 12‑week cystic fibrosis (CF) open label Phase 2 study; lung function (ppFEV1 and LCI) is being monitored in Class I CF subjects Received regulatory direction on pediatric development strategy from FDA (Type C meeting) for ornithine

2026-04-27 Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

SAN DIEGO --(BUSINESS WIRE)--Apr. 27, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for

2026-03-05 Arcturus Therapeutics to Attend Upcoming Investor Conference

SAN DIEGO --(BUSINESS WIRE)--Mar. 5, 2026-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the

2026-03-03 Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

ARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well tolerated ARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026 Cash runway extended into Q2 2028 Investor conference call at 4:30 p.m. ET today SAN DIEGO --(BUSINESS WIRE)--Mar.

Past events

Date Event Type
2026-11-16 Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration READ MORE Event
2026-11-11 Stifel 2026 Healthcare Conference (New York) | 1x1 Investor Meetings Conference
2026-11-09 Guggenheim's 3rd Annual Healthcare Innovation Conference (Boston) | Fireside Chat Conference
2026-11-05 Arcturus Therapeutics Third Quarter 2026 Earnings Call Earnings call
2026-11-05 Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress READ MORE Results publication
2026-10-26 Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026 READ MORE Results publication
2026-09-29 ROTH 5th Annual Healthcare Opportunities Conference (New York) | Investor Meetings Conference
2026-09-23 Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform | Presentation Presentation
2026-09-23 Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform READ MORE Event
2026-09-18 Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform READ MORE Event
2026-09-15 H.C. Wainwright 28th Annual Global Investment Conference (New York) | Presentation Conference
2026-09-10 Cantor Fitzgerald 12th Annual Global Healthcare Conference (New York) | Fireside Chat Conference
2026-09-09 Citi's 2026 Biopharma Back to School Conference (New York) | Fireside Chat Conference
2026-09-08 Wells Fargo 21st Annual Healthcare Conference (Boston) | Fireside Chat Conference
2026-08-31 Arcturus Therapeutics to Participate in Upcoming Investor Conferences READ MORE Conference
2026-08-11 Canaccord Genuity 46th Annual Growth Conference | Fireside Chat Conference
2026-08-11 Canaccord Genuity 46th Annual Growth Conference Conference
2026-08-06 Arcturus Therapeutics Second Quarter 2026 Earnings Call Earnings call
2026-08-06 Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress READ MORE Results publication
2026-07-28 Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026 READ MORE Results publication
2026-07-20 Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference READ MORE Conference
2026-07-02 Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis READ MORE Event
2026-06-04 Jefferies Global Healthcare Conference | Presentation Conference
2026-06-04 2026 Jefferies Global Healthcare Conference Conference
2026-05-26 Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference READ MORE Conference

Source: https://ir.arcturusrx.com/

Key facts CIK 1768224 CUSIP 03969T109 13F (30d) 172 filings 143 filers Visit website Investor relations